GUARDIAN™ CONNECT SYSTEM Continuous Glucose Monitor (CGM)

Guardian™ Connect is the only smart continuous glucose monitor (CGM) that helps patients on multiple daily injections (MDI) outsmart highs and lows. Using smarttechnology to predict where glucose levels are headed, the system alerts patients from 10 to 60 minutes before a glucose excursion, so they can take action in advance.

NOW APPROVED FOR BOTH iOS AND ANDROID™

 

REQUEST A DEMO

Overview

WITHOUT THE FULL GLUCOSE PICTURE, DIABETES CAN BE UNPREDICTABLE FOR PATIENTS ON INSULIN INJECTIONS

A graph of sensor glucose data.

 

The only CGM system that can alert your patients of potential highs and lows up to 60 minutes in advance. 

In a recent CareLink™ data analysis of real-world data,1 it was found that Guardian™ Connect system users avoided 65% of lows and 44% of high glucose episodes.*

WATCH VIDEO

SMART CGM FOR PATIENTS ON MDI

Patients may now avoid lows and highs.

The Guardian™ Connect CGM system monitors glucose levels day and night, sending precise readings automatically to the app.

Guardian™ Sensor 3

The system includes a small sensor that can be worn up to seven days and a slim, discreet Bluetooth® transmitter that can be worn in almost any situation. They work together to send precise glucose readings every five minutes.

CareLink data report displayed on a tablet screen.

AUTOMATIC UPLOADS TO
CARELINK™ SYSTEM

  • Anytime access to CGM data when patients link their CareLink™ account to your practice. 
  • Remote access for virtual appointments in three easy steps:
    1. Link and upload
    2. View
    3. Collaborate
Infographic displaying steps to connect CareLink system.

Sugar.IQTM Diabetes AssiStant App

Available for iOS devices.

  • Uses technology to continually analyze how your patients' glucose levels are reacting to food, insulin, and other factors. 
  • Reveals hidden patterns to provide personalized insights to help patients make smarter decisions.§

EXCLUSIVELY AVAILABLE FOR PATIENTS USING THE GUARDIANTM CONNECT SYSTEM.

sugar

The Sugar.IQ Diabetes Assistant app is available for download exclusively from the Apple app store

DOWNLOAD THE APP
Sugar.IQ diabetes assistant app screen displayed on a smartphone.

Request A DEMO

A sales representative can keep you informed about new and existing Medtronic products. For more information, please fill out the form.

* Indicates a required field.

By clicking Submit, I confirm that I have read and agree to the Authorization and permit Medtronic to use my contact information for the purposes described in the authorization. Read More.

Webinars

On-demand videos offer practical tips from clinical experts for using Medtronic Diabetes therapies to help you support patients.

WATCH NOW

MEDICAL EDUCATION PROGRAMS

Engage with real-world case studies and explore special considerations for therapy management

LEARN MORE

USER GUIDES AND MANUALS

Browse our library to find reference materials for your Medtronic Diabetes products.

VISIT LIBRARY
*

Low episodes defined as ≤ 70 mg/dL in sensor glucose level; high episode as ≥ 180 mg/dL in sensor glucose level.

Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance and provides access to Sugar.IQ™ insights that can inform users of clinically relevant glucose patterns.

Based on sensor glucose value with alerts turned on.

§

The system is intended to compliment, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained using a home blood glucose meter and not on values provided by the system.

1

Arunachalam S, et al. Poster presented at ADA 2019. 79th Scientific Sessions. June 7th-11th. San Francisco, California. #939-P; Data includes all US patients uploading voluntarily to CareLink™ Personal Software from June 2018 to Feb 2019 N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications

Important Safety Information: Guardian™ Connect CGM System
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.

Important Safety Information: Sugar.IQ™ App
The Sugar.IQ™ app (MMT-8100) helps manage diabetes by facilitating the logging and display of meal entries and sensor glucose (SG) data, tracking meal log entries, reporting insights of how meals affect glucose levels, and supporting good choices and trends with motivational messages. The app serves as an additional display for real-time CGM data from the Guardian™ Connect system through the CareLink™ Personal software. It is not intended to provide medical advice and should not be relied upon for such purpose. The app is not intended to replace the real-time display of the CGM data on the Guardian™ Connect app, control any functions of the connecting device, calculate insulin or other drug doses, or modify date or control functions of the Guardian™ Connect system. All therapy decisions should be made by the app user based on blood glucose (BG) measurements obtained from a BG meter. Changes to treatment should only be made in consultation with a healthcare professional (HCP). For complete details, consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.

The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.

Important Safety Information: CareLink™ Software
The CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult important safety information. and the appropriate CareLink™ User Guide at http://www.medtronicdiabetes.com/support/download-library/user-guides.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.

Android is a trademark of Google LLC.

The Android robot is reproduced or modified from work created and shared by Google and used according to terms described in the Creative Commons 3.0 Attribution License.

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.